Open Access Articles- Top Results for Methyl aminolevulinate

Methyl aminolevulinate

Methyl aminolevulinate
File:Methyl aminolevulinate.svg
Systematic (IUPAC) name
methyl 5-amino-4-oxo-pentanoate
Clinical data
AHFS/ Multum Consumer Information
33320-16-0 7pxY
PubChem CID 16052023
DrugBank DB00992 7pxY
ChemSpider 13180320 7pxY
ChEMBL CHEMBL1096562 7pxN
Chemical data
Formula C6H11NO3
145.156 g/mol
 14pxN (what is this?)  (verify)

Methyl aminolevulinate (MAL) is a drug used as a sensitizer in photodynamic therapy. It is a prodrug that is metabolized to protoporphyrin IX. It is marketed as Metvix.

Metvix cream is applied topically and some time later the skin is illuminated with a proprietary red light (630 nm) source (medical lamp 'Aktilite') to activate the photosensitiser.

Metvix is developed by Photocure and Galderma has bought all rights to Metvix.[1]

Approvals and indications

File:Phototherapy week.png
Interim result of phototherapy for actinic keratosis with Metvix one week after exposure. Patient has light skin and blue eyes.

Methyl aminolevulinate is approved in New Zealand for treatment of basal cell carcinoma.[2]

It is now approved in many countries and has been used to treat non-melanoma skin cancer (including basal cell carcinoma).[3]

It has some advantages over Levulan.[4]

It has been reported as controversial in some quarters, with severe pain allegedly being experienced by some patients. [5]


  1. ^ Photocure divests Metvix to Galderma
  2. ^ "Methyl aminolevulinate photodynamic therapy (MAL PDT)"
  3. ^ "New 5 Year Metvix-PDT Data Demonstrate Long-Term Efficacy & Reliability For NM Skin Cancer Treatment" 2006
  4. ^[dead link] Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy Photochemistry and Photobiology, Sep/Oct 2009 by O'Connor, Aisling E, Gallagher, William M, Byrne, Annette T
  5. ^

Lua error in package.lua at line 80: module 'Module:Buffer' not found.